Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in J Cancer Res Clin Oncol Retrieve available abstracts of 125 articles: HTML format

Single Articles

September 2025
1. CHEN X, Kong R, Qi Y, Li L, et al
   MiR-26b-5p mediates radioresistance and immunosuppression via targeting PRKCD in non-small cell lung cancer.
   J Cancer Res Clin Oncol. 2025;151:262.
   PubMed     Abstract available
   
   
   
2. SHI Y, Zhao D, Xiao Z, Wang Y, et al
   The impact of miRNAs on epithelial-mesenchymal transition in lung cancer and the latest advances in their use as diagnostic markers.
   J Cancer Res Clin Oncol. 2025;151:252.
   PubMed     Abstract available
   
   
   
3. KASTNER A, Kron A, Eilers L, Spier A, et al
   DigiNet: Optimizing personalized care for patients with stage IV non-small cell lung cancer (NSCLC) through a digitally connected provider network-analysis plan of a prospective multicenter cohort trial.
   J Cancer Res Clin Oncol. 2025;151:244.
   PubMed     Abstract available
   
   
   August 2025
4. WU X, Fang K, Huang W, Chen G, et al
   Combined small-cell lung cancer with adenocarcinoma: a rare case and literatures review.
   J Cancer Res Clin Oncol. 2025;151:230.
   PubMed     Abstract available
   
   
   
5. MANGUES-BAFALLUY I, Bernardez B, Martinez-Sesmero JM, Navarro-Ruiz A, et al
   Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study.
   J Cancer Res Clin Oncol. 2025;151:224.
   PubMed    
   
   
   July 2025
6. YANG J, Xu Q, Lu Y
   Decoding epithelial-fibroblast interactions in lung adenocarcinoma through single-cell and spatial transcriptomics.
   J Cancer Res Clin Oncol. 2025;151:221.
   PubMed     Abstract available
   
   
   
7. YILDIZ O, Eryilmaz MK, Gurbuz AF, Kaya BE, et al
   Small cell lung cancer differentiation in patients with driver mutant non-small cell lung cancer: a single center experience.
   J Cancer Res Clin Oncol. 2025;151:199.
   PubMed     Abstract available
   
   
   June 2025
8. WANG D, Qiu J, Li R, Tian H, et al
   Development and interpretation of machine learning-based prognostic models for predicting high-risk prognostic pathological components in pulmonary nodules: integrating clinical features, serum tumor marker and imaging features.
   J Cancer Res Clin Oncol. 2025;151:190.
   PubMed     Abstract available
   
   
   
9. ZHAO X, Fu W
   Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients.
   J Cancer Res Clin Oncol. 2025;151:182.
   PubMed     Abstract available
   
   
   
10. TAHERI P, Golden A
    A prognostic PET radiomic model for risk stratification in non-small cell lung cancer: integrating radiogenomics and clinical features to predict survival and uncover tumor biology insights.
    J Cancer Res Clin Oncol. 2025;151:180.
    PubMed     Abstract available
    
    
    May 2025
11. WU KW, Deng SY, Zhang XF, Zheng DW, et al
    Thoracoscopy-guided thoracic paravertebral block using dexmedetomidine in combination with ropivacaine for postoperative analgesia after thoracoscopic radical resection of lung cancer: a randomized controlled trial.
    J Cancer Res Clin Oncol. 2025;151:158.
    PubMed     Abstract available
    
    
    April 2025
12. WANG Z, Zeng Y, Jiang H, Luo C, et al
    Management strategies for primary lung carcinosarcoma: a case study and comprehensive literature review.
    J Cancer Res Clin Oncol. 2025;151:147.
    PubMed     Abstract available
    
    
    
13. WU S, Hu C, Hu P, He W, et al
    RAF1 promotes anlotinib resistance in non-small cell lung cancer by inhibiting apoptosis.
    J Cancer Res Clin Oncol. 2025;151:138.
    PubMed     Abstract available
    
    
    
14. SHIGETA N, Murakami S, Yamamoto K, Yokose T, et al
    Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2025;151:139.
    PubMed     Abstract available
    
    
    March 2025
15. ZHAO QY, Liu WJ, Wang JG, Li H, et al
    Increasing cisplatin exposure promotes small-cell lung cancer transformation after a shift from glucose metabolism to fatty acid metabolism.
    J Cancer Res Clin Oncol. 2025;151:126.
    PubMed     Abstract available
    
    
    
16. HUANG G, Chen L
    Correction: Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma.
    J Cancer Res Clin Oncol. 2025;151:108.
    PubMed    
    
    
    February 2025
17. SHENG J, Jiao J, Yan N, Pan H, et al
    De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature.
    J Cancer Res Clin Oncol. 2025;151:82.
    PubMed     Abstract available
    
    
    
18. WANG M, Zhang S, Yi D, Ou Y, et al
    Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2025;151:78.
    PubMed     Abstract available
    
    
    
19. LI B, Wu Y, Zhang Y, Hu C, et al
    Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database.
    J Cancer Res Clin Oncol. 2025;151:68.
    PubMed     Abstract available
    
    
    
20. WANG M, Liu H, Zhang R, Li R, et al
    Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review.
    J Cancer Res Clin Oncol. 2025;151:62.
    PubMed     Abstract available
    
    
    
21. SUMINAGA K, Nomizo T, Yoshida H, Ozasa H, et al
    The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study.
    J Cancer Res Clin Oncol. 2025;151:61.
    PubMed     Abstract available
    
    
    January 2025
22. ENDO S, Imai H, Mouri A, Tsukamoto K, et al
    Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged >/= 75 years) with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2025;151:43.
    PubMed     Abstract available
    
    
    
23. HU M, Meng X, Wang T, Wang Y, et al
    Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung metastasis and tumorigenesis.
    J Cancer Res Clin Oncol. 2025;151:38.
    PubMed     Abstract available
    
    
    
24. GANESH SK, Devi CS
    Exploring the interactions of rapamycin with target receptors in A549 cancer cells: insights from molecular docking analysis.
    J Cancer Res Clin Oncol. 2025;151:31.
    PubMed     Abstract available
    
    
    December 2024
25. DAI Q, Yao X, Zhang Y, Chai Q, et al
    CTSG is a prognostic marker involved in immune infiltration and inhibits tumor progression though the MAPK signaling pathway in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;151:21.
    PubMed     Abstract available
    
    
    November 2024
26. RISCHKE N, Kanbach J, Haug U
    Age differences in the treatment of lung cancer-a cohort study among 42,000 patients from Germany.
    J Cancer Res Clin Oncol. 2024;150:503.
    PubMed     Abstract available
    
    
    
27. LI S, Yuan T, Yuan J, Zhu B, et al
    Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy.
    J Cancer Res Clin Oncol. 2024;150:501.
    PubMed     Abstract available
    
    
    
28. IBRULI O, Rose F, Beleggia F, Schmitt A, et al
    A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade.
    J Cancer Res Clin Oncol. 2024;150:496.
    PubMed     Abstract available
    
    
    October 2024
29. LIU Y, Lin W, Gu Y, Lu C, et al
    Dysregulation of SIGLEC1 in non-small cell lung cancer: prognostic implications and immunomodulatory role-a multicenter cohort study.
    J Cancer Res Clin Oncol. 2024;150:481.
    PubMed     Abstract available
    
    
    
30. MALMROS K, Kirova N, Kotarsky H, Carlsen D, et al
    3D cultivation of non-small-cell lung cancer cell lines using four different methods.
    J Cancer Res Clin Oncol. 2024;150:472.
    PubMed     Abstract available
    
    
    
31. ZUO Y, Liu Q, Li N, Li P, et al
    Explainable (18)F-FDG PET/CT radiomics model for predicting EGFR mutation status in lung adenocarcinoma: a two-center study.
    J Cancer Res Clin Oncol. 2024;150:469.
    PubMed     Abstract available
    
    
    
32. YANG L, Li M, Liu Y, Jiang Z, et al
    Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:453.
    PubMed     Abstract available
    
    
    September 2024
33. WANG Q, Deng Z, Lu C, Chen L, et al
    A prospective study to compare the diagnostic accuracy of (99m)Tc-CNDG SPECT/CT and contrast-enhanced CT in staging of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:430.
    PubMed     Abstract available
    
    
    
34. FANG Y, Wan J, Zeng Y
    Use machine learning to predict pulmonary metastasis of esophageal cancer: a population-based study.
    J Cancer Res Clin Oncol. 2024;150:420.
    PubMed     Abstract available
    
    
    
35. GU G, Liu C, Zhu X, Yang Y, et al
    Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.
    J Cancer Res Clin Oncol. 2024;150:413.
    PubMed     Abstract available
    
    
    
36. KIM SH, Seong H, Lee J, Ahn HY, et al
    The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung.
    J Cancer Res Clin Oncol. 2024;150:409.
    PubMed     Abstract available
    
    
    August 2024
37. LI X, Lu Y, Zhao J, Yu Y, et al
    Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:395.
    PubMed     Abstract available
    
    
    
38. UHLENBRUCH M, Kruger S
    Effect of TTF-1 expression on progression free survival of immunotherapy and chemo-/immunotherapy in patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:394.
    PubMed     Abstract available
    
    
    
39. NGUYEN OTD, Fotopoulos I, Nost TH, Markaki M, et al
    The HUNT lung-SNP model: genetic variants plus clinical variables improve lung cancer risk assessment over clinical models.
    J Cancer Res Clin Oncol. 2024;150:389.
    PubMed     Abstract available
    
    
    July 2024
40. RATHOR A, Malik PS, Tanwar P, Khurana S, et al
    'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma.
    J Cancer Res Clin Oncol. 2024;150:371.
    PubMed     Abstract available
    
    
    
41. CHANG JX, Zhang M, Lou LL, Chu HY, et al
    KIS, a target of SOX4, regulates the ID1-mediated enhancement of beta-catenin to facilitate lung adenocarcinoma cell proliferation and metastasis.
    J Cancer Res Clin Oncol. 2024;150:366.
    PubMed     Abstract available
    
    
    
42. CHEN H, Xu Y, Lin H, Wan S, et al
    A prognostic framework for predicting lung signet ring cell carcinoma via a machine learning based cox proportional hazard model.
    J Cancer Res Clin Oncol. 2024;150:364.
    PubMed     Abstract available
    
    
    
43. ZHANG S, Guo C, Xu J, Qian P, et al
    Quantitative assessment of intertarget position variations based on 4D-CT and 4D-CBCT simulations in single-isocenter multitarget lung stereotactic body radiation therapy.
    J Cancer Res Clin Oncol. 2024;150:359.
    PubMed     Abstract available
    
    
    
44. FOTOPOULOS I, Nguyen OTD, Nost TH, Markaki M, et al
    Promising microRNAs in pre-diagnostic serum associated with lung cancer up to eight years before diagnosis: a HUNT study.
    J Cancer Res Clin Oncol. 2024;150:355.
    PubMed     Abstract available
    
    
    
45. HE L, Chen H, Ruan B, He L, et al
    UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway.
    J Cancer Res Clin Oncol. 2024;150:335.
    PubMed     Abstract available
    
    
    June 2024
46. YEGHAIAN M, Tareco Bucho TM, de Bruin M, Schmitz A, et al
    Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
    J Cancer Res Clin Oncol. 2024;150:329.
    PubMed     Abstract available
    
    
    
47. FENG Y, Qian R, Cui D, Luan J, et al
    Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3.
    J Cancer Res Clin Oncol. 2024;150:312.
    PubMed     Abstract available
    
    
    
48. LI Y, Wan Y, Yang X, Chen P, et al
    Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting.
    J Cancer Res Clin Oncol. 2024;150:290.
    PubMed     Abstract available
    
    
    May 2024
49. HUANG BT, Lin PX, Luo LM, Wang Y, et al
    Incorporating the inflammation-related parameters enhances the performance of the nomogram for predicting local control in lung cancer patients treated with stereotactic body radiation therapy.
    J Cancer Res Clin Oncol. 2024;150:284.
    PubMed     Abstract available
    
    
    
50. CHEN Z, Cai Y, Ou T, Zhou H, et al
    Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990-2019.
    J Cancer Res Clin Oncol. 2024;150:282.
    PubMed     Abstract available
    
    
    
51. LI X, Wu D, Tang J, Wu Y, et al
    The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
    J Cancer Res Clin Oncol. 2024;150:271.
    PubMed     Abstract available
    
    
    
52. WANG X, Xu Z, Zhao S, Song J, et al
    A novel subtype based on driver methylation-transcription in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:269.
    PubMed     Abstract available
    
    
    
53. DANG J, Xu G, Guo G, Zhang H, et al
    Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    J Cancer Res Clin Oncol. 2024;150:255.
    PubMed     Abstract available
    
    
    
54. LI R, Tong R, Zhang JL, Zhang Z, et al
    Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:246.
    PubMed     Abstract available
    
    
    
55. MENG X, Peng F, Yu S, Chi X, et al
    Knockdown of NADK promotes LUAD ferroptosis via NADPH/FSP1 axis.
    J Cancer Res Clin Oncol. 2024;150:228.
    PubMed     Abstract available
    
    
    
56. CHEN Q, Cheng J, Wang L, Lv X, et al
    Primary lung cancer in children and adolescents.
    J Cancer Res Clin Oncol. 2024;150:225.
    PubMed     Abstract available
    
    
    April 2024
57. TAMURA K, Okuma Y, Nomura S, Fukuda A, et al
    Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
    J Cancer Res Clin Oncol. 2024;150:216.
    PubMed     Abstract available
    
    
    
58. BILGIN B, Kuralay Y, Yucel S
    Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.
    J Cancer Res Clin Oncol. 2024;150:215.
    PubMed     Abstract available
    
    
    
59. CHEN Y, Ji Y, Shen L, Li Y, et al
    High core 1beta1,3-galactosyltransferase 1 expression is associated with poor prognosis and promotes cellular radioresistance in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:214.
    PubMed     Abstract available
    
    
    
60. LIU W, Zhou D, Zhang L, Huang M, et al
    Characteristics and outcomes of cancer patients admitted to intensive care units in cancer specialized hospitals in China.
    J Cancer Res Clin Oncol. 2024;150:205.
    PubMed     Abstract available
    
    
    
61. WU X, Zhao X, Zhou C, Wei N, et al
    Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:188.
    PubMed     Abstract available
    
    
    
62. HONG S, Lee JH, Heo JY, Suh KJ, et al
    Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
    J Cancer Res Clin Oncol. 2024;150:186.
    PubMed     Abstract available
    
    
    
63. WANG Y, Lyu D, Cheng C, Zhou T, et al
    Preoperative nomogram for predicting spread through air spaces in clinical-stage IA non-small cell lung cancer using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
    J Cancer Res Clin Oncol. 2024;150:185.
    PubMed     Abstract available
    
    
    
64. ZHAO R, Guan X, Zhang P, Liu Y, et al
    Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.
    J Cancer Res Clin Oncol. 2024;150:175.
    PubMed     Abstract available
    
    
    
65. SAKASHITA M, Motoi N, Yamamoto G, Gambe E, et al
    An algorithm-based technique for counting mitochondria in cells using immunohistochemical staining of formalin-fixed and paraffin-embedded sections.
    J Cancer Res Clin Oncol. 2024;150:172.
    PubMed     Abstract available
    
    
    March 2024
66. JIANG L, Yang P, Liu Y, Li J, et al
    BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
    J Cancer Res Clin Oncol. 2024;150:162.
    PubMed     Abstract available
    
    
    
67. BANAT M, Potthoff AL, Hamed M, Borger V, et al
    Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment.
    J Cancer Res Clin Oncol. 2024;150:136.
    PubMed     Abstract available
    
    
    
68. GE Y, Zhan Y, He J, Li J, et al
    PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data.
    J Cancer Res Clin Oncol. 2024;150:135.
    PubMed     Abstract available
    
    
    
69. JU W, Lin L, Zhang Q, Lv X, et al
    GATA6 inhibits the biological function of non-small cell lung cancer by modulating glucose metabolism.
    J Cancer Res Clin Oncol. 2024;150:126.
    PubMed     Abstract available
    
    
    
70. SHIJUBOU N, Sumi T, Kubo T, Sasaki K, et al
    Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2024;150:125.
    PubMed     Abstract available
    
    
    
71. MA M, Luo M, Liu Q, Zhong D, et al
    Influence of abdominal fat distribution and inflammatory status on post-operative prognosis in non-small cell lung cancer patients: a retrospective cohort study.
    J Cancer Res Clin Oncol. 2024;150:111.
    PubMed     Abstract available
    
    
    February 2024
72. KRIZOVA L, Benesova I, Zemanova P, Spacek J, et al
    Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2024;150:99.
    PubMed     Abstract available
    
    
    
73. WANG Y, Dong A, Jin M, Li S, et al
    TEP RNA: a new frontier for early diagnosis of NSCLC.
    J Cancer Res Clin Oncol. 2024;150:97.
    PubMed     Abstract available
    
    
    
74. NIU L, Wu H, Gao R, Chen L, et al
    Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.
    J Cancer Res Clin Oncol. 2024;150:94.
    PubMed     Abstract available
    
    
    
75. KURIBAYASHI T, Ohashi K, Nishii K, Ninomiya K, et al
    Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    J Cancer Res Clin Oncol. 2024;150:89.
    PubMed     Abstract available
    
    
    
76. ZHOU W, Yeerkenbieke G, Zhang Y, Zhou M, et al
    Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors.
    J Cancer Res Clin Oncol. 2024;150:90.
    PubMed     Abstract available
    
    
    
77. XIA X, Ge Y, Ge F, Gu P, et al
    MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial-mesenchymal transition in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:88.
    PubMed     Abstract available
    
    
    
78. FAN X, Zhang Q, Qin S, Ju S, et al
    CircBRIP1: a plasma diagnostic marker for non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:83.
    PubMed     Abstract available
    
    
    
79. DU C, Tan L, Xiao X, Xin B, et al
    Detection of the DNA methylation of seven genes contribute to the early diagnosis of lung cancer.
    J Cancer Res Clin Oncol. 2024;150:77.
    PubMed     Abstract available
    
    
    
80. WU Y, Zhang J, Zhou W, Yuan Z, et al
    Prognostic factors in extensive-stage small cell lung cancer patients with organ-specific metastasis: unveiling commonalities and disparities.
    J Cancer Res Clin Oncol. 2024;150:74.
    PubMed     Abstract available
    
    
    
81. CHENG X, Zhou J, Chen Y, Zhao Y, et al
    Patterns and trends of mortality from metastatic colorectal cancer in Shanghai, China from 2005 to 2021: a population-based retrospective analysis.
    J Cancer Res Clin Oncol. 2024;150:68.
    PubMed     Abstract available
    
    
    January 2024
82. LIANG Y, Zhang X, Peng J, Liu J, et al
    Vitamin D-mediated tsRNA-07804 triggers mitochondrial dysfunction and suppresses non-small cell lung cancer progression by targeting CRKL.
    J Cancer Res Clin Oncol. 2024;150:51.
    PubMed     Abstract available
    
    
    
83. ZHANG H, Lin J, Yahaya BH
    Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:44.
    PubMed     Abstract available
    
    
    
84. CUI Y, Lin J, Sun D, Zhang H, et al
    Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate.
    J Cancer Res Clin Oncol. 2024;150:45.
    PubMed     Abstract available
    
    
    
85. WANG X, He J, Li J, Wu C, et al
    Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).
    J Cancer Res Clin Oncol. 2024;150:43.
    PubMed     Abstract available
    
    
    
86. ZHANG J, Han W, Guo J, Zhang C, et al
    Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.
    J Cancer Res Clin Oncol. 2024;150:42.
    PubMed     Abstract available
    
    
    
87. YUCE TH, Ak G, Metintas S, Dundar E, et al
    BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
    J Cancer Res Clin Oncol. 2024;150:38.
    PubMed     Abstract available
    
    
    
88. HUANG BT, Wang Y, Lin PX
    Developing a clinical-radiomic prediction model for 3-year cancer-specific survival in lung cancer patients treated with stereotactic body radiation therapy.
    J Cancer Res Clin Oncol. 2024;150:34.
    PubMed     Abstract available
    
    
    
89. LIU JJ, Shen WB, Qin QR, Li JW, et al
    Prediction of positive pulmonary nodules based on machine learning algorithm combined with central carbon metabolism data.
    J Cancer Res Clin Oncol. 2024;150:33.
    PubMed     Abstract available
    
    
    
90. LU J, Feng Y, Guo K, Sun L, et al
    Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
    J Cancer Res Clin Oncol. 2024;150:25.
    PubMed     Abstract available
    
    
    
91. ZHU L, Qin J
    Predictive biomarkers for immunotherapy response in extensive-stage SCLC.
    J Cancer Res Clin Oncol. 2024;150:22.
    PubMed     Abstract available
    
    
    
92. MENG X, Zhao X, Zhou B, Song W, et al
    FSTL3 is associated with prognosis and immune cell infiltration in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:17.
    PubMed     Abstract available
    
    
    
93. XU J, Chen H, Fan W, Qiu M, et al
    Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction.
    J Cancer Res Clin Oncol. 2024;150:7.
    PubMed     Abstract available
    
    
    December 2023
94. BAI Y, Liu Y, Wu J, Miao R, et al
    CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels.
    J Cancer Res Clin Oncol. 2023;149:16827-16836.
    PubMed     Abstract available
    
    
    
95. ZHANG W, He Z, Liang F, Gong J, et al
    Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
    J Cancer Res Clin Oncol. 2023;149:16763-16778.
    PubMed     Abstract available
    
    
    
96. LU Y, Li Q, Xu L, Zheng Y, et al
    Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma.
    J Cancer Res Clin Oncol. 2023;149:16501-16510.
    PubMed     Abstract available
    
    
    
97. YI M, Shi J, Tan X, Zhang X, et al
    Integration and deconvolution methodology deciphering prognosis-related signatures in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:16441-16460.
    PubMed     Abstract available
    
    
    
98. LIU W, Xia J, Du Q, Wang J, et al
    Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:16365-16376.
    PubMed     Abstract available
    
    
    
99. MENG X, Song W, Zhou B, Liang M, et al
    Prognostic and immune correlation analysis of mitochondrial autophagy and aging-related genes in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:16311-16335.
    PubMed     Abstract available
    
    
    
100. ZHANG J, Song L, Li G, Liang A, et al
     Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.
     J Cancer Res Clin Oncol. 2023;149:17199-17213.
     PubMed     Abstract available
     
     
     
101. SHIRAISHI S, Sugimoto M, Tokuuye K
     Salivary metabolites as novel independent predictors of radiation pneumonitis.
     J Cancer Res Clin Oncol. 2023;149:17559-17566.
     PubMed     Abstract available
     
     
     November 2023
102. XU M, Hao Y, Shi Z, Song Z, et al
     Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Nov 17. doi: 10.1007/s00432-023-05490.
     PubMed     Abstract available
     
     
     
103. XIONG Y, Gu F, Cui J, Liu Y, et al
     Construction and validation of a novel prognostic nomogram for predicting overall survival in lung adenocarcinoma patients with different patterns of metastasis.
     J Cancer Res Clin Oncol. 2023;149:15039-15053.
     PubMed     Abstract available
     
     
     
104. LV H, Shao Y, Chen QS, Song WJ, et al
     A case of endobronchial metastasis of colon cancer mimics sarcoidosis, and a review of related literature.
     J Cancer Res Clin Oncol. 2023;149:15287-15292.
     PubMed     Abstract available
     
     
     
105. LIU J, Wei L
     Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2023;149:14577-14596.
     PubMed     Abstract available
     
     
     
106. WANG Y, Yan C, Zhang C, Yu E, et al
     The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib.
     J Cancer Res Clin Oncol. 2023;149:16069-16073.
     PubMed     Abstract available
     
     
     
107. ZHOU J, Fang P, Liang Z, Li X, et al
     Causal relationship between lung diseases and risk of esophageal cancer: insights from Mendelian randomization.
     J Cancer Res Clin Oncol. 2023;149:15679-15686.
     PubMed     Abstract available
     
     
     
108. ZHANG G, Guan H, Ning YL, Yao K, et al
     Osimertinib resistance prognostic gene signature: STRIP2 is associated with immune infiltration and tumor progression in lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2023;149:15573-15588.
     PubMed     Abstract available
     
     
     
109. MILJANIC M, Nwachukwu C, Rahimi A
     Definitive ablative stereotactic partial breast irradiation in early stage inoperable breast cancer.
     J Cancer Res Clin Oncol. 2023;149:15553-15559.
     PubMed     Abstract available
     
     
     
110. CHANG Y, Xing H, Shang Y, Liu Y, et al
     Preoperative predicting invasiveness of lung adenocarcinoma manifesting as ground-glass nodules based on multimodal images of dual-layer spectral detector CT radiomics models.
     J Cancer Res Clin Oncol. 2023;149:15425-15438.
     PubMed     Abstract available
     
     
     
111. GAO R, Gao Y, Zhang J, Zhu C, et al
     A nomogram for predicting invasiveness of lung adenocarcinoma manifesting as pure ground-glass nodules: incorporating subjective CT signs and histogram parameters based on artificial intelligence.
     J Cancer Res Clin Oncol. 2023;149:15323-15333.
     PubMed     Abstract available
     
     
     
112. ZHANG L, Guan M, Zhang X, Yu F, et al
     Machine-learning and combined analysis of single-cell and bulk-RNA sequencing identified a DC gene signature to predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2023;149:13553-13574.
     PubMed     Abstract available
     
     
     October 2023
113. KUBO S, Kobayashi N, Matsumoto H, Somekawa K, et al
     Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Oct 25. doi: 10.1007/s00432-023-05457.
     PubMed     Abstract available
     
     
     
114. MOREIRA RS, da Silva MM, de Melo Vasconcelos CF, da Silva TD, et al
     Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Oct 16. doi: 10.1007/s00432-023-05437.
     PubMed     Abstract available
     
     
     
115. YIN T, Liu K, Shen Y, Wang Y, et al
     Alteration of serum bile acids in non-small cell lung cancer identified by a validated LC-MS/MS method.
     J Cancer Res Clin Oncol. 2023 Oct 10. doi: 10.1007/s00432-023-05434.
     PubMed     Abstract available
     
     
     
116. LI C, Zhang Y, Xia Q, Hao B, et al
     Multi-omics analysis revealed the mitochondrial-targeted drug combination to suppress the development of lung cancer.
     J Cancer Res Clin Oncol. 2023 Oct 2. doi: 10.1007/s00432-023-05376.
     PubMed     Abstract available
     
     
     September 2023
117. BRATOVA M, Skrickova J, Matusikova M, Hrabcova K, et al
     Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Sep 28. doi: 10.1007/s00432-023-05431.
     PubMed     Abstract available
     
     
     
118. WU R, Zhang B, He M, Kang Y, et al
     MicroRNA biomarkers and their use in evaluating the prognosis of lung cancer.
     J Cancer Res Clin Oncol. 2023 Sep 20. doi: 10.1007/s00432-023-05404.
     PubMed     Abstract available
     
     
     
119. ZHAO K, Xia C, Qiu M, Yang Z, et al
     Lobar or sublobar resection for early-stage second primary lung cancer
     J Cancer Res Clin Oncol. 2023 Sep 19. doi: 10.1007/s00432-023-05396.
     PubMed     Abstract available
     
     
     
120. HUANG F, Cui J, Wan J, Yuan X, et al
     SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis.
     J Cancer Res Clin Oncol. 2023 Sep 19. doi: 10.1007/s00432-023-05416.
     PubMed     Abstract available
     
     
     
121. ZHANG Y, Xu H, Pi S, Tan H, et al
     The prognostic and immunological role of FKBP1A in an integrated muti-omics cancers analysis, especially lung cancer.
     J Cancer Res Clin Oncol. 2023 Sep 16. doi: 10.1007/s00432-023-05362.
     PubMed     Abstract available
     
     
     
122. VOORN MJJ, Bastiaansen EMW, Schroder CD, van Kampen-van den Boogaart VEM, et al
     A qualitative stakeholder analysis of beliefs, facilitators, and barriers for a feasible prehabilitation program before lung cancer surgery.
     J Cancer Res Clin Oncol. 2023 Sep 5. doi: 10.1007/s00432-023-05298.
     PubMed     Abstract available
     
     
     
123. XIONG L, Zhu C, Lu Y, Chen M, et al
     Serum THBS2 is a potential biomarker for the diagnosis of non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Sep 2. doi: 10.1007/s00432-023-05330.
     PubMed     Abstract available
     
     
     
124. DONG H, Wang X, Qiu Y, Lou C, et al
     Establishment and visualization of a model based on high-resolution CT qualitative and quantitative features for prediction of micropapillary or solid components in invasive lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2023;149:10519-10530.
     PubMed     Abstract available
     
     
     
125. JIANG B, Hu L, Dong D, Guo Z, et al
     TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
     J Cancer Res Clin Oncol. 2023;149:10041-10052.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.